Regulations.gov document
Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into…
Other · FDA-2023-D-0026 · posted Apr 6, 2023
Key facts
| Document ID | FDA-2023-D-0026-0002 |
|---|---|
| Title | Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints For Regulatory Decision-Making Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders |
| Document type | Other |
| Subtype | Guidance |
| Agency | FDA |
| Docket | FDA-2023-D-0026 |
| Posted | Apr 6, 2023 |
| Comment period opens | Apr 6, 2023 |
| Comments due | Jul 6, 2023 |
At a glance
- No Open for comment
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: